secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001370053-25-000052
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio rosnilimab Phase 2b RA data shows best-in-disease profile with JAK-like efficacy
--------------------------------------------------------------------------------

- 424-patient Phase 2b trial: rosnilimab achieved JAK-like efficacy on CDAI LDA, remission, and ACR70 through six months.
- Favorable safety: no treatment-related SAEs, <2% discontinuation due to AEs, low injection site reactions.
- Responses durable for at least 2 months off drug; pain VAS improved ~50 points from baseline ~65 to ~15.
- 69% of patients achieved CDAI LDA by Week 14; max response rates not yet observed due to strict continuation criteria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000052/0001370053-25-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000052/anab-20250603.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer